SCHEMBL5578664

SCHEMBL5578664

O=S(=O)(c1ccc(Cl)cc1)N1Cc2ccccc2C2(CCN(Cc3cccc4c3OCO4)CC2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 2/20 0.41
DRD2 P14416 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
SIGMAR1 Q99720 2/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PKM P14618 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
FAAH O00519 1/20 0.38
TP53 P04637 1/20 0.38
HTT P42858 1/20 0.37
GLRA3 O75311 1/20 0.36
GLRB P48167 1/20 0.36
CYP2D6 P10635 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578491 0.81 GLRA3 (0.41) DRD1DRD2SMN1; SMN2MAPTMEN1
SCHEMBL5578875 0.76 KMT2A (0.62) DRD2SIGMAR1MEN1ALDH1A1KMT2A
SCHEMBL5578499 0.76 SIGMAR1 (0.53) DRD2SMN1; SMN2SIGMAR1MEN1KMT2A
SCHEMBL5578577 0.75 SMN1; SMN2 (0.48) DRD1DRD2SMN1; SMN2MAPTMEN1
SCHEMBL5578847 0.73 MAPT (0.50) SMN1; SMN2MAPTMEN1KMT2AHTT
SCHEMBL5582419 0.72 MEN1 (0.46) SMN1; SMN2MAPTMEN1ALDH1A1PKM
SCHEMBL5578671 0.70 KMT2A (0.36) SMN1; SMN2MEN1ALDH1A1KMT2ACYP2D6
SCHEMBL5579027 0.69 STS (0.48) MEN1KMT2A
SCHEMBL12935742 0.65 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1CYP3A4
SCHEMBL5779729 0.64 DRD2 (0.36) DRD1DRD2SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US claimed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
WO-2005063745-A9 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARM INC (US) 2007-02-01 WO disclosed
WO-2005063745-A9 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARM INC (US) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof REN, AVPR2, RECQL DRD1 152/4885DRD2 126/4885SMN1; SMN2 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.